News & Updates
ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy
In vitro study of the ELIAS Cancer Immunotherapy (ECI®) showed personalized T cell immunotherapy initiated a significant immune response against target cancer cells. OLATHE, Kan., August 10, 2022 -- ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI®) at the 2022 American College of Veterinary Internal Medicine Forum. ECI is an adoptive cell therapy that stimulates a patient’s immune system to recognize and attack cancers. ECI uses a personalized vaccine made from a patient’s own cancer cells to “prime” the immune cells to recognize the cancer. These primed [...]
Can We Treat Cancer Without Chemotherapy?
Cancer is the leading cause of death in dogs, and in humans it is second only to heart disease. For decades, chemotherapy has been the only option and a necessary evil to treat cancer. Most of us know someone who has gone through chemo, and side effects can significantly impact quality of life during and after treatment. Chemotherapy targets cells at different stages of the cell cycle, and because cancer cells often form more quickly than normal cells, chemo can be effective in destroying cells and preventing them from growing, dividing, and making more cells. Unfortunately, “chemo drugs can’t [...]
PODCAST: ELIAS CEO talks immunotherapy and canine osteosarcoma on Dog Cancer Answers
ELIAS Animal Health CEO, Tammie Wahaus, was a recent guest on the Dog Cancer Answers podcast to discuss how the ELIAS Cancer Immunotherapy (ECI) works, the role of a healthy immune system in successful immunotherapy, and why we chose to focus on canine osteosarcoma first. Listen to the episode below, or read the full transcript at Dog Cancer Answers online. Listen to more episodes of the Dog Cancer Answers podcast here.